<DOC>
	<DOCNO>NCT01986855</DOCNO>
	<brief_summary>This study evaluate efficacy safety ertugliflozin ( MK-8835/PF-04971729 ) participant type 2 diabetes mellitus Stage 3 Chronic Kidney Disease ( CKD ) inadequate glycemic control background antihyperglycemic therapy . The duration trial 67 week . This consist 1-week Screening Period , 10-week wash-off period metformin , need , 2-week placebo run-in period , 52-week double-blind treatment period , 14-day post-treatment follow-up period . The primary objective trial ass A1C-lowering efficacy addition ertugliflozin compare addition placebo underlie hypothesis addition treatment ertugliflozin provide great reduction A1C compare addition placebo ; primary objective test 5-mg 15-mg dos ertugliflozin .</brief_summary>
	<brief_title>A Study Efficacy Safety Ertugliflozin Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control Antihyperglycemic Therapy ( MK-8835-001 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Diagnosis T2DM On stable diabetes therapy ( diet/exercise therapy alone antihyperglycemic agent [ AHA ] monotherapy combination therapy ) least 6 week prior study participation OR metformin ( without diet/exercise therapy AHA therapy ) willing undergo 10week metformin washoff period Body Mass Index ( BMI ) great equal 18.0 kg/m^2 Male , postmenopausal female surgically sterile female If female reproductive potential , agree remain abstinent use ( partner use ) 2 acceptable combination birth control participate trial 14 day last use study drug . History type 1 diabetes mellitus history ketoacidosis History specific type diabetes ( e.g. , genetic syndrome , secondary pancreatic diabetes , diabetes due endocrine disorder , drug chemicalinduced , postorgan transplant ) History nephrotic range proteinuria hypoalbuminemia edema History rapidly progressive glomerulonephritis , lupus nephritis , renal systemic vasculitis , renal artery stenosis renovascular hypertension , ischemic nephropathy History familial renal glucosuria History renal dialysis renal transplant renal disease require treatment immunosuppressive agent A know hypersensitivity intolerance ( sodiumglucose cotransporter 2 ) SGLT2 inhibitor On weightloss program weightloss medication medication associate weight change weight stable Has undergone bariatric surgery within past 12 month Has treat rosiglitazone SGLT2 inhibitor within 12 week study participation Has active , obstructive uropathy indwell urinary catheter History myocardial infarction , unstable angina , arterial revascularization , stroke , transient ischemic attack , New York Heart Association ( NYHA ) functional class IIIIV heart failure within 3 month study participation A history malignancy â‰¤5 year prior study participation , except adequately treat basal squamous cell skin cancer situ cervical cancer Known history Human Immunodeficiency Virus ( HIV ) Has blood dyscrasia disorder cause hemolysis unstable red blood cell clinically significant hematological disorder ( aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) A medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , primary biliary cirrhosis , active symptomatic gallbladder disease Has clinically significant malabsorption condition If take thyroid replacement therapy , stable dose least 6 week prior study participation Has previously randomize study ertugliflozin Has participate study involve investigational drug within 30 day prior study participation Has undergone surgical procedure within 6 week prior study participation Has positive urine pregnancy test Is pregnant breastfeeding , plan conceive trial , include 14 day follow last dose study medication Planning undergo hormonal therapy preparation donate egg trial , include 14 day follow last dose study medication Excessive consumption alcoholic beverage binge drinking Has donate blood blood product within 6 week study participation plan donate blood blood product time trial</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>